Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dorzolamide-Timolol for Incomplete Anti-VEGF Responders in Wet AMD
NCT03034772Phase 3Completed
- Sponsor
- Wills Eye Hospital
- Start
- Feb 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dorzolamide + timolol in neovascular age-related macular degeneration (NVAMD), sponsored by Wills Eye Hospital. Started Feb 2017; status: completed.
02
Drugs
dorzolamide + timolol
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03034772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03034772.